IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases 10,065 Shares of Personalis, Inc. (NASDAQ:PSNL)

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Personalis, Inc. (NASDAQ:PSNL) by 66.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 25,168 shares of the company’s stock after purchasing an additional 10,065 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Personalis were worth $145,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after buying an additional 5,654 shares in the last quarter. Olympiad Research LP bought a new stake in shares of Personalis in the fourth quarter worth about $59,000. SG Americas Securities LLC acquired a new stake in shares of Personalis during the fourth quarter worth about $63,000. Raymond James Financial Inc. bought a new position in shares of Personalis during the 4th quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Personalis in the 4th quarter valued at approximately $87,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PSNL has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Personalis in a research note on Friday, February 28th. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Craig Hallum initiated coverage on Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price target on the stock. Finally, Needham & Company LLC reduced their price objective on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Personalis currently has a consensus rating of “Buy” and an average target price of $7.80.

Personalis Trading Up 1.1 %

Shares of PSNL stock opened at $3.62 on Friday. The firm’s fifty day moving average price is $4.60 and its two-hundred day moving average price is $4.80. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The firm has a market capitalization of $319.51 million, a P/E ratio of -2.15 and a beta of 1.73.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.09. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The company had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. As a group, equities research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.